June 22, 2015

A Potential New Treatment for Aggressive Lymphomas

More efficient, safer therapy may be on horizon

Figure-1_690x380

More than 60,000 people will be diagnosed with non-Hodgkin’s lymphoma this year and of these people, about 20,000 will die from it. Diffuse large B-cell lymphoma (DLBCL), one type of non-Hodgkin’s lymphoma, is particularly aggressive and accounts for about 25 percent to 35 percent of yearly diagnoses. While people’s responses to treatment vary greatly, if left untreated, DLBCL lessens survival and people live anywhere from a few weeks to a few months. A new study published in the journal Leukemia shows that a new treatment works well in mouse models and might provide new options to patients with DLBCL.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

Understanding how lymphomas grow

Neetu Gupta, PhD, has been examining B lymphocytes and trying to identify what spurs their growth and survival. While normal B cells play an important role in the immune system by providing antibody-mediated protection, aberrantly functioning B cells can contribute to aggressive lymphomas and autoimmune disorders, such as lupus.

“I am interested in figuring out what activates B cells and what keeps them alive in health and disease,” says Dr. Gupta, of the Department of Immunology at Cleveland Clinic’s Lerner Research Institute.

To this end, she examined samples of primary tumor biopsy samples from DLBCL patients and patient-derived cell lines. “The lymphomas contain sheets and sheets of B cells that continuously grow and survive,” she says. “Interestingly, these cells have high levels of phosphorylated ezrin-radixin-moesin proteins.”

She suspected that ERMs played a role in the proliferation of the unhealthy B cells. To gain a better understanding, she looked at their role both in cell culture and in mouse models. The results from these studies reinforced her belief: ERMs enable the growth of cancerous B cells.

Coming up with a targeted treatment

Armed with an understanding of the role that ERMs play in B cell function, Dr. Gupta looked at ways to inhibit their function. She employed genetic mutants and knockdown approaches, as well as a novel small molecule that binds directly to ezrin. In her paper in Leukemia, she demonstrates that all three approaches abrogate lymphoma growth and that the small molecule inhibition approach is highly effective in mouse models.

“Utilizing in vitro and in vivo assays, we have identified that a small molecule inhibitor of ezrin disrupts DLBCL growth. We transplanted DLBCL cell line xenografts in mice to test the utility and efficacy of inhibiting ezrin as a target for DLBCL,” she says.

Advertisement

What’s exciting is that targeting ezrin to treat cancer might provide a much more efficient, safer therapy.

“These cancer cells are smart: They have a lot of different signaling pathways that allow them to survive. The ERM proteins act really upstream of these pathways. When you target so upstream, many of those pathways that are downstream will be simultaneously deactivated,” she says.

The small molecule inhibitor disrupts the survival of the cancerous B cells and causes them to die, without affecting healthy cells.

“It is exciting because most of the existing treatment regimen kill both good and bad cells,” she says.

While the results with this lead molecule seem promising, Dr. Gupta is modifying it to improve its efficiency and potency. She is also testing different routes of availability of this molecule in animal models so that patients can take it orally or intravenously.

Immunochemistry images of DLBCL cells treated using antibodies.

Immunochemistry images of DLBCL cells treated using antibodies.

Advertisement

The importance of targeted treatments

Cancer cells want to survive and often adapt to hostile environments to thrive. The current treatment, a combination of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP), works effectively for less than 50 percent of DLBCL patients. Additionally, R-CHOP kills both cancerous cells and functional immune cells, leaving patients with weakened immune systems. This means that if people experience an infection their bodies are less adept at fighting it off. Moreover, R-CHOP does not work in relapsed disease, meaning that the need for new and improved therapies is great. Finding that small molecules bind to ezrin and inhibit lymphoma growth means new treatments are on the horizon.

“The identification of novel therapies is imperative to improve prognosis and survival of these patients,” says Dr. Gupta.

While this new small molecule treatment is not immediately available for clinical trials, Dr. Gupta believes it represents a strong option for cancer management in the near future.

“This would be a novel way in which to target these aggressive lymphomas without a lot of the toxic side effects,” she says. “A lot of work remains. It’s sort of in its infancy right now [but] there is a lot of potential.”

Related Articles

Doctors working on MGUS screening study
March 18, 2024
Pilot Study Aims for Early Identification of Multiple Myeloma Precursor Among Black Patients

First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses

Physician with patient
March 6, 2024
Targeting Uncontrolled Erythrocytosis in Polycythemia Vera with Rusfertide

Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels

Doctor measuring patient's waist size
February 26, 2024
Impact of Obesity on GVHD & Transplant Outcomes in Hematologic Malignancies

Findings highlight an association between obesity and an increased incidence of moderate-severe disease

Physician with patient
February 21, 2024
Strategies for Improving Clinical Trial Equity

Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access

How antibody drug conjugates work
February 13, 2024
Real-World Use of Trastuzumab Deruxtecan

Key learnings from DESTINY trials

24-CNR-4545611-CQD-Podcast-967×544
February 1, 2024
Possibilities of CRISPR Technology (Podcast)

Gene editing technology offers promise for treating multiple myeloma and other hematologic malignancies, as well as solid tumors

Disparities in multiple myeloma
January 25, 2024
Major Study Identifies Global Disparities in Drug Toxicity for Multiple Myeloma Treatment

Study of 401,576 patients reveals differences in cancer burdens as well as overall survival

Dr. Shilpa Gupta
December 27, 2023
A New Standard Emerges in Advanced Urothelial Carcinoma After Decades of First-Line Chemotherapy

Enfortumab plus pembrolizumab reduced risk of death by 53% compared with platinum-based chemotherapy

Ad